KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Fundamental Analysis

NASDAQ:KNSA • GB00BRXB0C07

47.17 USD
+1.78 (+3.92%)
At close: Feb 19, 2026
47.17 USD
0 (0%)
After Hours: 2/19/2026, 7:11:49 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, KNSA scores 6 out of 10 in our fundamental rating. KNSA was compared to 521 industry peers in the Biotechnology industry. KNSA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KNSA has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make KNSA suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year KNSA was profitable.
  • KNSA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
  • In multiple years KNSA reported negative operating cash flow during the last 5 years.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • KNSA has a Return On Assets of 5.04%. This is amongst the best in the industry. KNSA outperforms 90.98% of its industry peers.
  • KNSA has a better Return On Equity (6.71%) than 90.79% of its industry peers.
  • KNSA's Return On Invested Capital of 5.12% is amongst the best of the industry. KNSA outperforms 91.75% of its industry peers.
Industry RankSector Rank
ROA 5.04%
ROE 6.71%
ROIC 5.12%
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • KNSA's Profit Margin of 6.01% is amongst the best of the industry. KNSA outperforms 89.44% of its industry peers.
  • KNSA's Operating Margin of 6.38% is amongst the best of the industry. KNSA outperforms 90.02% of its industry peers.
  • Looking at the Gross Margin, with a value of 87.52%, KNSA belongs to the top of the industry, outperforming 90.02% of the companies in the same industry.
  • KNSA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.38%
PM (TTM) 6.01%
GM 87.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KNSA is destroying value.
  • The number of shares outstanding for KNSA has been increased compared to 1 year ago.
  • Compared to 5 years ago, KNSA has more shares outstanding
  • KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • KNSA has an Altman-Z score of 12.34. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
  • KNSA's Altman-Z score of 12.34 is amongst the best of the industry. KNSA outperforms 84.45% of its industry peers.
  • There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.34
ROIC/WACC0.55
WACC9.33%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 3.85 indicates that KNSA has no problem at all paying its short term obligations.
  • KNSA has a Current ratio of 3.85. This is comparable to the rest of the industry: KNSA outperforms 46.26% of its industry peers.
  • A Quick Ratio of 3.51 indicates that KNSA has no problem at all paying its short term obligations.
  • KNSA has a Quick ratio of 3.51. This is comparable to the rest of the industry: KNSA outperforms 44.53% of its industry peers.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.51
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • KNSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 421.43%, which is quite impressive.
  • The Revenue has grown by 55.68% in the past year. This is a very strong growth!
  • Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 122.27% on average per year.
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%

3.2 Future

  • The Earnings Per Share is expected to grow by 47.22% on average over the next years. This is a very strong growth
  • KNSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.42% yearly.
EPS Next Y254.67%
EPS Next 2Y114.83%
EPS Next 3Y80.02%
EPS Next 5Y47.22%
Revenue Next Year59.43%
Revenue Next 2Y45.78%
Revenue Next 3Y35.52%
Revenue Next 5Y24.42%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 104.82, KNSA can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 89.44% of the companies listed in the same industry.
  • KNSA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.09.
  • The Price/Forward Earnings ratio is 29.57, which means the current valuation is very expensive for KNSA.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 92.13% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of KNSA to the average of the S&P500 Index (27.98), we can say KNSA is valued inline with the index average.
Industry RankSector Rank
PE 104.82
Fwd PE 29.57
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • KNSA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KNSA is cheaper than 90.79% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, KNSA is valued cheaper than 93.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF 35.15
EV/EBITDA 73.44
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of KNSA may justify a higher PE ratio.
  • A more expensive valuation may be justified as KNSA's earnings are expected to grow with 80.02% in the coming years.
PEG (NY)0.41
PEG (5Y)N/A
EPS Next 2Y114.83%
EPS Next 3Y80.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KNSA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (2/19/2026, 7:11:49 PM)

After market: 47.17 0 (0%)

47.17

+1.78 (+3.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-16
Earnings (Next)04-21
Inst Owners91.98%
Inst Owner Change-57.51%
Ins Owners3.34%
Ins Owner Change-20.04%
Market Cap3.58B
Revenue(TTM)597.97M
Net Income(TTM)35.92M
Analysts86.15
Price Target56.1 (18.93%)
Short Float %7.02%
Short Ratio5.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.24%
Min EPS beat(2)-30.25%
Max EPS beat(2)23.78%
EPS beat(4)2
Avg EPS beat(4)-1408.01%
Min EPS beat(4)-5782.35%
Max EPS beat(4)156.77%
EPS beat(8)4
Avg EPS beat(8)-745.86%
EPS beat(12)7
Avg EPS beat(12)-468.4%
EPS beat(16)10
Avg EPS beat(16)-331.07%
Revenue beat(2)2
Avg Revenue beat(2)5.46%
Min Revenue beat(2)4.99%
Max Revenue beat(2)5.94%
Revenue beat(4)3
Avg Revenue beat(4)2.96%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)8.84%
Revenue beat(16)11
Avg Revenue beat(16)8.11%
PT rev (1m)0.52%
PT rev (3m)10.74%
EPS NQ rev (1m)-9.54%
EPS NQ rev (3m)-14.08%
EPS NY rev (1m)-5.45%
EPS NY rev (3m)-10.85%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)0.76%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 104.82
Fwd PE 29.57
P/S 5.98
P/FCF 35.15
P/OCF 34.76
P/B 6.68
P/tB 6.88
EV/EBITDA 73.44
EPS(TTM)0.45
EY0.95%
EPS(NY)1.6
Fwd EY3.38%
FCF(TTM)1.34
FCFY2.85%
OCF(TTM)1.36
OCFY2.88%
SpS7.89
BVpS7.06
TBVpS6.86
PEG (NY)0.41
PEG (5Y)N/A
Graham Number8.46
Profitability
Industry RankSector Rank
ROA 5.04%
ROE 6.71%
ROCE 6.48%
ROIC 5.12%
ROICexc 12.74%
ROICexgc 13.63%
OM 6.38%
PM (TTM) 6.01%
GM 87.52%
FCFM 17.01%
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 75.86%
Cap/Sales 0.19%
Interest Coverage 250
Cash Conversion 259.48%
Profit Quality 283.24%
Current Ratio 3.85
Quick Ratio 3.51
Altman-Z 12.34
F-Score8
WACC9.33%
ROIC/WACC0.55
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
EPS Next Y254.67%
EPS Next 2Y114.83%
EPS Next 3Y80.02%
EPS Next 5Y47.22%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
Revenue Next Year59.43%
Revenue Next 2Y45.78%
Revenue Next 3Y35.52%
Revenue Next 5Y24.42%
EBIT growth 1Y245.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year441.76%
EBIT Next 3Y125.72%
EBIT Next 5YN/A
FCF growth 1Y3968.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4071.47%
OCF growth 3YN/A
OCF growth 5YN/A

KINIKSA PHARMACEUTICALS INTE / KNSA FAQ

Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a fundamental rating of 6 / 10 to KNSA.


Can you provide the valuation status for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a valuation rating of 7 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Undervalued.


Can you provide the profitability details for KINIKSA PHARMACEUTICALS INTE?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for KNSA stock?

The Price/Earnings (PE) ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 104.82 and the Price/Book (PB) ratio is 6.68.


How financially healthy is KINIKSA PHARMACEUTICALS INTE?

The financial health rating of KINIKSA PHARMACEUTICALS INTE (KNSA) is 7 / 10.